Dyslipidemia is one of the major modifiable risk factors associated with atherosclerotic cardiovascular disease. Appropriate modification of lipid profiles reduces the progression of atherosclerosis in vessel walls across all vascular beds. The management of dyslipidemia has evolved over the last several decades, especially since the discovery of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, also known as statins. Statin use in atherosclerotic heart disease is well described in observational and prospective placebo-controlled studies, citing both lipid-lowering and pleiotropic effects. However, the effect of statins and other lipid-lowering agents on noncoronary arterial beds (the aorta, arteries to the extremities, renal, and carotid arteries) is less understood. This article is part 2 of a 2-part review, with part 1 having focused on lipid metabolism and the downstream effects of lipids on the development of atherosclerosis. The current review (part 2) will discuss trials, retrospective reviews, and observational cohort studies regarding the use of statins and/or other lipid-lowering drugs for primary and secondary prevention of peripheral noncoronary atherosclerotic disease.
DuffGLMcMG. Pathology of atherosclerosis. Am J Med. 1951;11(1):92–108.
2.
KeysATaylorHLBlackburnHBrozekJAndersonJTSimonsonE. Coronary heart disease among Minnesota business and professional men followed fifteen years. Circulation. 1963;28:381–95.
3.
KannelWBCastelliWPGordonTMcNamaraPM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann Intern Med. 1971;74(1):1–12.
4.
EndoA. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569–1582.
5.
AlbertsAW. Lovastatin and simvastatin—inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology. 1990;77(suppl 4):14–21.
6.
StoneNJRobinsonJGLichtensteinAH. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S1–S45.
7.
O’DonnellTFJrPassmanMA. Clinical practice guidelines of the Society for Vascular Surgery (SVS) and the American Venous Forum (AVF)—Management of venous leg ulcers. Introduction. J Vasc Surg. 2014;60(2 suppl):1S–2S.
8.
JovinISDuggalMEbisuK. Comparison of the effect on long-term outcomes in patients with thoracic aortic aneurysms of taking versus not taking a statin drug. Am J Cardiol. 2012;109(7):1050–1054.
9.
SteinLHBergerJTranquilliMElefteraidesJA. Effect of statin drugs on thoracic aortic aneurysms. Am J Cardiol. 2013;112(8):1240–1245.
10.
PeriardDGuessousIMazzolaiLHaeslerEMonneyPHayozD. Reduction of small infrarenal abdominal aortic aneurysm expansion rate by statins. VASA. 2012;41(1):35–42.
11.
SchoutenOvan LaanenJHBoersmaE. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32(1):21–26.
12.
SukhijaRAronowWSSandhuRKakarPBabuS. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol. 2006;97(2):279–280.
13.
FeeneyJMBurnsKStaffI. Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm. J Am Coll Surg. 2009;209(1):41–46.
14.
HirschATHartmanLTownRJVirnigBA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209–215.
15.
CriquiMHLangerRDFronekA. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.
16.
CriquiMHNinomiyaJKWingardDLJiMFronekA. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol. 2008;52(21):1736–1742.
17.
ParikhSVSayaSDivanjiP. Risk of death and myocardial infarction in patients with peripheral arterial disease undergoing percutaneous coronary intervention (from the National Heart, Lung and Blood Institute Dynamic Registry). Am J Cardiol. 2011;107(7):959–964.
18.
TomochikaYOkudaFTanakaN. Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16(8):955–962.
19.
PitsavosCEAggeliKIBarbetseasJD. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1998;82(12):1484–1488.
20.
YogoMSasakiMAyaoriM. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: serial magnetic resonance imaging observations from RAPID study. Atherosclerosis. 2014;232(1):31–39.
21.
TawakolAFayadZAMoggR. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013;62(10):909–917.
22.
KawaharaTSuzukiG. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation. 2013;127(23):2327–2335.
23.
Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
24.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet. 1994;344(8934):1383–1389.
25.
OhmanEMBhattDLStegPG. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006;151(4):786. e1–e10.
26.
ArmstrongEJChenDCWestinGG. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697.
27.
FeringaHHKaragiannisSEvan WaningVH. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease. J Vasc Surg. 2007;45(5):936–943.
28.
FeringaHHvan WaningVHBaxJJ. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47(6):1182–1187.
29.
SchillingerMExnerMMlekuschW. Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J. 2004;25(9):742–748.
30.
AronowWSNayakDWoodworthSAhnC. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92(6):711–712.
31.
MondilloSBalloPBarbatiR. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114(5):359–364.
32.
MohlerERIIIHiattWRCreagerMA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481–1486.
33.
McDermottMMGuralnikJMGreenlandP. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107(5):757–761.
34.
WardRPLeeperNJKirkpatrickJNLangRMSorrentinoMJWilliamsKA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. Int J Cardiol. 2005;104(3):264–268.
35.
AbbruzzeseTAHavensJBelkinM. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg. 2004;39(6):1178–1185.
36.
HenkePKBlackburnSProctorMC. Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. J Vasc Surg. 2004;39(2):357–365.
37.
SuckowBDKraissLWSchanzerA. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg. 2015;61(1):126–133.
38.
WestinGGArmstrongEJ2BangH3. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63(7):682–690.
39.
MozaffarianDBenjaminEJGoAS. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322.
40.
ByingtonRPFurbergCDCrouseJRIIIEspelandMABondMG. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;76(9):54C–59C.
41.
FurbergCDAdamsHPJrApplegateWB. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90(4):1679–1687.
42.
HodisHNMackWJLaBreeL. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med. 1996;124(6):548–556.
43.
KroonAAvan AstenWNStalenhoefAF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med. 1996;125(12):945–954.
44.
MacMahonSSharpeNGambleG. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation. 1998;97(18):1784–1790.
45.
MercuriMBondMGSirtoriCR. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med. 1996;101(6):627–634.
46.
PlehnJFDavisBRSacksFM. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation. 1999;99(2):216–223.
47.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349–1357.
48.
ShepherdJCobbeSMFordI. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307.
49.
ByingtonRPDavisBRPlehnJF. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation. 2001;103(3):387–392.
50.
SeverPSDahlöfBPoulterNR. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64(suppl 2):43–60.
51.
BaigentCKeechAKearneyPM. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
52.
WatersDDLaRosaJCBarterP. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006;48(9):1793–1799.
53.
AmarencoPBogousslavskyJCallahanAIII. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–559.
54.
EverettBMGlynnRJMacFadyenJGRidkerPM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143–150.
55.
HackamDGWoodwardMNewbyLK. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124(20):2233–2242.
56.
RitchieJGreenDKalraPA. Current views on the management of atherosclerotic renovascular disease. Ann Med. 2012;44(suppl 1):S98–S110.
57.
CheungCMShurrabAEBuckleyDL. MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease. Kidney Int. 2006;69(4):715–722.
58.
SilvaVSMartinLCFrancoRJ. Pleiotropic effects of statins may improve outcomes in atherosclerotic renovascular disease. Am J Hypertens. 2008;21(10):1163–1168.
59.
BaxLWoittiezAJKouwenbergHJ. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840–848, W150–W151.
60.
CooperCJMurphyTPMatsumotoA. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152(1):59–66.
61.
ASTRAL Investigators, WheatleyKIvesNGrayR. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953–1962.
62.
HackamDGWuFLiP. Statins and renovascular disease in the elderly: a population-based cohort study. Eur Heart J. 2011;32(5):598–610.
63.
ParfreyPSFoleyRN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10(7):1606–1615.
64.
SarnakMJLeveyASSchoolwerthAC. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–2169.
65.
WannerCKraneVMärzW. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248.
66.
FellströmBCJardineAGSchmiederRE. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407.
67.
BaigentCLandrayMJReithC. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192.
68.
KasteleinJJAkdimFStroesES. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431–1443.
69.
FlegJLMeteMHowardBV. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–2205.
70.
Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785–794. e10.
71.
WestAMAndersonJDMeyerCH. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218(1):156–162.
72.
CaliffRMLokhnyginaYCannonCP. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J. 2010;159(5):705–709.
73.
Brown BG1, ZhaoXQChaitA. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583–1592.
74.
VillinesTCStanekEJDevinePJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55(24):2721–2726.
75.
AIM-HIGH Investigators, BodenWEProbstfieldJLAndersonT. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
76.
HPS2-THRIVE Collaborative Group, LandrayMJHaynesRHopewellJC. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
77.
BrunnerGYangEYKumarA. The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis. 2013;231(2):371–377.
78.
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357(9260):905–910.
79.
KeechASimesRJBarterP. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861.
80.
ACCORD Study Group, GinsbergHNElamMBLovatoLC. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574.
81.
DavidsonMHRosensonRSMakiKC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). Arterioscler Thromb Vasc Biol, 2014;34(6):1298–1306.
82.
YeXQianCLiuJSt PeterWL. Lower risk of major cardiovascular events associated with adherence to colesevelam HCI. Pharmacotherapy. 2013;33(10):1062–1070.
83.
SawayamaYShimizuCMaedaN. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol. 2002;39(4):610–616.
84.
CastañoGMás FerreiroRFernándezLGámezRIllnaitJFernándezC. A long-term study of policosanol in the treatment of intermittent claudication. Angiology. 2001;52(2):115–125.
85.
RosenblumSBHuynhTAfonsoA. Discovery of 1-(4-fluorophenyl)-(3 R)-[3-(4-fluorophenyl)-(3 S)-hydroxypropyl]-(4 S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem. 1998;41(6):973–980.
86.
GrundySMCleemanJIMerzCN. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–732.
87.
TothPPDavidsonMH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5(6):455–462.
88.
CannonCPGiuglianoRPBlazingMA. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156(5):826–832.
89.
GrundySMMokHYZechLBermanM. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981;22(1):24–36.
90.
BergeKGCannerPL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol. 1991;40(suppl 1):S49–S51.
91.
LeeJMRobsonMDYuLMShirodariaCC. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009;54(19):1787–1794.
92.
DayspringTPokrywkaG. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Curr Atheroscler Rep. 2006;8(5):356–364.
93.
Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–27.
94.
ElkelesRSDiamondJRPoulterC. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998;21(4):641–648.
95.
EricssonCG. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress. Eur Heart J. 1998;19(suppl H):H37–H41.
96.
MeadeTZuhrieRCookCCooperJ. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002;325(7373):1139.
97.
RossSD’MelloMAnandSS. Effect of bile acid sequestrants on the risk of cardiovascular events: a Mendelian randomization analysis. Circ Cardiovasc Genet. 2015;8(4):618–627.
98.
InsullWJr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99(3):257–273.
99.
ChenJTWesleyRShamburekRDPucinoFCsakoG. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25(2):171–183.
100.
BarterPJBrewerHBJrChapmanMJHennekensCHRaderDJTallAR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol, 2003;23(2):160–167.
101.
BarterPJCaulfieldMErikssonM. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122.
102.
BotsMLVisserenFLEvansGW. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370(9582):153–160.
103.
KasteleinJJvan LeuvenSIBurgessL. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356(16):1620–1630.
104.
NissenSETardifJCNichollsSJ. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–1316.
105.
LüscherTFTaddeiSKaskiJC. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J. 2012;33(7):857–865.
106.
SchwartzGGOlssonAGAbtM. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–2099.
107.
The Cleveland Clinic. Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2012. Web site. https://clinicaltrials.gov/ct2/show/record/NCT01687998. Published September 12, 2012. Accessed November 18, 2015. Updated January 25, 2016.
108.
Eli Lilly and Company. The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014. Web site. https://clinicaltrials.gov/ct2/show/record/NCT02227784. Published August 26, 2014. Accessed November 18, 2015. Updated December 23, 2015.
109.
University of Oxford. REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2010. Web site. https://clinicaltrials.gov/ct2/show/NCT01252953. Published November 24, 2010. Accessed November 18, 2015. Updated May 29, 2015.
